Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Vaccines01:30

Cancer Vaccines

237
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
237
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

720
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
720
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting LRRC15-expressing fibroblasts holds therapeutic potential to ameliorate inflammation and fibrosis in autoimmune diseases.

Rheumatology (Oxford, England)·2026
Same author

PARP7 protects the lung epithelial barrier from diverse environmental threats.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Nucleotide metabolic rewiring enables NLRP3 inflammasome hyperactivation in obesity.

Science (New York, N.Y.)·2026
Same author

The STING pathway drives noninflammatory neurodegeneration in NGLY1 deficiency.

The Journal of experimental medicine·2025
Same author

The IFN I response in tumor cells is shaped by PARP7-p300/CBP interactions through distinct loss- and gain-of-function mechanisms.

bioRxiv : the preprint server for biology·2025
Same author

Dynamic STING repression orchestrates immune cell development and function.

Science immunology·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 9, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

219

Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer.

Cong Xing1, Xintao Tu1, Wanwan Huai1

  • 1Department of Immunology, UT Southwestern Medical Center, Dallas, Texas.

Cancer Research
|May 6, 2025
PubMed
Summary

Targeting Three-prime repair exonuclease 1 (TREX1) with small molecules or knockout cells enhances antitumor immunity. TREX1 inhibition suppresses tumors and boosts immune responses, offering new cancer immunotherapy strategies.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

140
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.3K

Related Experiment Videos

Last Updated: May 9, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

219
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

140
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.3K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Three-prime repair exonuclease 1 (TREX1) degrades cytosolic DNA, preventing cGAS-STING pathway activation.
  • Cancer cells upregulate TREX1 under genotoxic stress, evading type I interferon (IFN-I) antitumor immunity.
  • Targeting TREX1 presents a strategy to enhance antitumor immunity and therapeutic outcomes.

Purpose of the Study:

  • To identify small-molecule inhibitors (SMIs) of TREX1.
  • To evaluate the therapeutic potential of TREX1 inhibition in cancer models.
  • To explore TREX1 knockout cancer cells as an autologous cancer vaccine.

Main Methods:

  • High-throughput screening of TREX1 small-molecule inhibitors (SMIs).
  • Assessing compound 296 efficacy in cell-free assays, cancer cell lines, and mouse models.
  • Generating and analyzing Trex1 knockout cancer cells and inducible whole-body Trex1 knockout mice.

Main Results:

  • Compound 296 selectively inhibited TREX1, induced IFN-I signaling, and suppressed tumor growth in mice.
  • TREX1 inhibition stimulated T cell infiltration and synergized with immune checkpoint blockade.
  • Trex1 knockout cancer cells acted as autologous vaccines, providing protection against tumor challenge and metastasis.
  • Sustained TREX1 loss demonstrated broad antitumor activity and immune safety in adult mice.

Conclusions:

  • TREX1 inhibition via SMIs or knockout strategies shows significant antitumor efficacy.
  • TREX1 targeting can enhance innate and adaptive immune responses against cancer.
  • TREX1-targeted therapies, including SMIs and cancer vaccines, offer promising avenues for cancer immunotherapy.